HomeLONGTERM CareLongterm CareCould Alzheimer’s actually be an autoimmune condition?

Could Alzheimer’s actually be an autoimmune condition?

Published on

New theory details how Alzheimer’s could be a chronic autoimmune condition that attacks the brain.

By 2030, nearly a million Canadians will be living with dementia. The vast majority will be diagnosed with Alzheimer’s disease, the most common form of dementia.

Alzheimer’s impacts more than 50 million people around the world, with a new person being diagnosed every three seconds. Yet, despite more than 200 clinical trials in the past 30 years, there are no disease modifying therapeutics to prevent, halt or treat Alzheimer’s.

“We need new ways of thinking about this disease, and we need them now,” says Dr. Donald Weaver, a Senior Scientist at the Krembil Brain Institute.

Dr. Weaver is the author of a recent paper detailing a new theory of Alzheimer’s – not as a brain disease, but as a chronic autoimmune condition that attacks the brain. This novel research was recently published in the journal of the Alzheimer’s Association, Alzheimer’s & Dementia.

[Watch this video to learn more about a new theory of Alzheimer’s as an autoimmune condition]

“We don’t think of Alzheimer’s as fundamentally a disease of the brain. We think of it as a disease of the immune system within the brain,” says Dr. Weaver.

“To date, most of the approaches in Alzheimer’s research have been based upon the theory that a protein called beta-amyloid, which is supposedly abnormal in the brain, clumps up. And when it clumps up, it kills brain cells.”

“But we believe beta-amyloid is right where it should be. It acts as an immunopeptide – a messenger within our immune system – so that, if we have head trauma, beta-amyloid repairs it. If a virus or a bacteria comes along, beta-amyloid is there to fight it.”

And that’s where the problem occurs, says Dr. Weaver.

“Beta-amyloid gets confused and can’t tell the difference between a bacteria and a brain cell and so it inadvertently attacks our own brain cells. This, then, becomes what we call an autoimmune disease. The immune system is actually attacking the host, our brain.”

This new theory of Alzheimer’s as an autoimmune condition has been getting a lot of attention internationally.

Dr. Weaver was announced as one of the recipients of the coveted Oskar Fischer Prize, awarded to scientists worldwide who are investigating new theories of Alzheimer’s. His recent essay ‘Alzheimer’s might not be primarily a brain disease. A new theory suggests it’s an autoimmune condition’ in The Conversation – an independent source of news from the academic and research community, has been viewed more than a million times and translated into several languages, including French, Spanish, Indonesian and Bulgarian.

“Tangible rethinking about Alzheimer’s disease as an autoimmune disease, and beta-amyloid as a normal part of our immune system, opens the door to new avenues and approaches to develop innovative and much-needed new therapies,” says Dr. Weaver.

“I have spent the last 30 years trying to come up with new approaches and new drugs to treat Alzheimer’s disease. We’re pretty excited in our lab. We think that this autoimmune theory is very sound. We think that it does represent a significant step forward and a new way of thinking and we’re excited about finding the molecules that hopefully, one day, leads up to a very useful drug.”

This article was submitted by UHN News.

Latest articles

New approach opens door to better-targeted treatments and faster drug discovery for complex diseases

McGill University researchers have developed an artificial intelligence tool that can identify small groups of cells most responsible...

Canadian Cancer Society urges lowering colorectal cancer screening age to 45

The Canadian Cancer Society (CCS) is calling on provinces and territories to lower the...

Unleashing natural killer cells against cancer

Researchers at McGill University have developed a new strategy to enhance natural killer (NK) cells, enabling them to better penetrate tumour defenses and destroy cancer cells. Using small-molecule drugs to temporarily boost NK cell activity—rather than permanent genetic modification—the approach showed strong results against multiple hard-to-treat cancers in preclinical studies. The scalable, ready-to-use therapy could make immunotherapy faster, safer, and more accessible, with future clinical trials planned for aggressive cancers like acute myeloid leukemia.

Doctors report false health information, lack of health data sharing put patient care at risk

Canada's doctors are concerned that false health information and disconnected health systems are putting...

More like this

Aging in place needs more than good intentions — it needs smart infrastructure

Supportive smart homes should be treated as core infrastructure in modern aging policy By Dr....

Canada’s Hospitals Can’t Solve the Seniors Care Crisis Alone

Across Canada, hospitals are under enormous pressure, with lengthy wait times and beds filled...

Small Care Homes to support aging population

HN Summary • Vancouver Coastal Health is launching Small Care Homes, a home-like long-term care...

Hospital to Home program aims to reduce ER visits

HN Summary • Windsor Regional Hospital, in partnership with SE Health, has launched the Hospital...

Compassionate Care for Older Adults with Dementia

HN Summary • Baycrest’s interdisciplinary, resident-centred approach addresses the behavioural symptoms of dementia by identifying...

Slower-walking seniors at risk for falls benefit most from home-based exercise program

HN Summary • New research shows a home-based strength and balance exercise program can significantly...